Investment analysts at StockNews.com assumed coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) in a report released on Tuesday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Trading Down 9.6 %
Shares of TTNP opened at $3.48 on Tuesday. Titan Pharmaceuticals has a 12-month low of $3.03 and a 12-month high of $14.80. The company has a market cap of $3.18 million, a PE ratio of -0.67 and a beta of 1.19. The stock has a 50-day moving average price of $3.66 and a 200-day moving average price of $4.02.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last announced its earnings results on Thursday, March 20th. The specialty pharmaceutical company reported ($0.85) earnings per share for the quarter.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Further Reading
- Five stocks we like better than Titan Pharmaceuticals
- What is Short Interest? How to Use It
- Energy Transfer: Powering Data With Dividends and Diversification
- Investing In Preferred Stock vs. Common Stock
- Qualcomm Stock Is Coiling for a Breakout
- Using the MarketBeat Stock Split Calculator
- Is Alphabet Too Cheap to Ignore After Its Recent Correction?
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
